OPuS-4: An open-label study to evaluate the long-term safety of avoralstat in subjects with hereditary angioedema

Trial Profile

OPuS-4: An open-label study to evaluate the long-term safety of avoralstat in subjects with hereditary angioedema

Discontinued
Phase of Trial: Phase III

Latest Information Update: 12 Aug 2016

At a glance

  • Drugs Avoralstat (Primary)
  • Indications Angioedema
  • Focus Adverse reactions
  • Acronyms OPuS 4
  • Sponsors BioCryst Pharmaceuticals
  • Most Recent Events

    • 16 Feb 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 02 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top